ReviewCureus2026
Global Perspective on Fertility-Sparing Surgical Oncology in Gynaecology: A Narrative Literature Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fertility-sparing surgery (FSS) has become a significant therapeutic option for young women with early-stage gynaecologic malignancies, aiming to balance effective cancer treatment with preservation of reproductive potential. However, the results are different based on the type of tumour, method of treatment, and mechanism of patient selection. This narrative literature review aimed to synthesise the current evidence on FSS oncology in gynaecology worldwide. The literature search included predominantly retrospective cohort studies, along with prospective cohort, cross-sectional, case-control, and randomised controlled studies, published between 1st January 2015 and 31st March 2026. The outcomes assessed were fertility preservation rates, pregnancy outcomes, live births, obstetric complications, oncologic outcomes (overall survival and recurrence), and prognostic factors affecting treatment success. Fertility preservation rates ranged from 55% to 100%, with rates exceeding 75% among patients with earlier-stage disease. Pregnancy outcomes were optimised in selected patients through the use of assisted reproductive technology (ART), including in vitro fertilisation (IVF). Conception occurred either spontaneously or through ART, with conception rates varying among women who attempted pregnancy. The live birth rates were between 20% and over 80%, but preterm delivery and obstetric complications were common. Across most included studies, the five-year overall survival rate exceeded 90% among patients with early-stage disease. Nevertheless, recurrence rates ranged from 1% to >20%, depending on tumour characteristics. Tumour size exceeding 2 cm, lymphovascular space invasion, and high-stage disease were consistently identified as significant predictors of recurrence and low disease-free survival. Current evidence suggests that FSS may be a safe and effective treatment option for carefully selected patients with early-stage gynaecological cancers while preserving reproductive potential. Fertility and survival outcomes should be optimised with the use of standardised protocols and long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.